PHILADELPHIA, PA – October 31, 2018 – ControlRad, Inc., a medical technology company focused on dramatically reducing unnecessary radiation exposure to patients and physicians during fluoroscopic procedures, announced today that a non-disclosed global medical device leader has invested in a second tranche in ControlRad.
“The new partnership will help accelerate our 2019 commercial launch while better positioning us to execute on our mission to reduce patient & medical staff radiation exposure during X-ray guided procedures,” said Guillaume Bailliard, President and CEO of ControlRad. “I am extremely pleased that a respected, long-term oriented industry leader shares our vision of the future.”
The details of the transaction are not disclosed.
ControlRad is a privately-held medical technology company developing innovative products that dramatically reduce the lifetime risk of radiation exposure from fluoroscopically guided interventional procedures (FGIP) for patients and healthcare professionals. These products are designed to improve safety without compromising image quality or workflow. This is accomplished with an integrated set of proprietary components which optimize the X-ray beam to deliver optimal image quality in the clinically-relevant region while maintaining appropriate resolution in the periphery. ControlRad is headquartered in Philadelphia and has engineering development facilities in Kfar Saba, Israel. For more information, visit http://www.controlrad.com.